Steven Carl Quay
Medical Practice at Eastlake Ave, Seattle, WA

2012017, Jul 5, 2012

Aug 5, 2011

13/204485

Alexis Kays LEONARD - Maple Valley WA, US
Joshua Orion SESTAK - Lawrence KS, US
Henry R. COSTANTINO - Woodinville WA, US
Anthony P. SILENO - Mendham NY, US
Lalit Raj PEDDAKOTA - San Diego CA, US
Kayvon Emile SHARGHI - Chevy Chase MD, US
Garland M. BELLAMY - Santa Fee NM, US
Jason Philip GESTY - Seattle WA, US
Steven C. QUAY - Seattle WA, US

A61K 38/11, A61P 25/28, A61P 25/24, A61P 25/00, A61P 25/22

514 116

Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.

2007021, Sep 13, 2007

Jun 7, 2005

11/570068

Steven Quay - Seattle WA, US
Henry Costantino - Woodinville WA, US

A61K 9/12, A61K 38/21

424045000, 424085500

Compositions and methods are provided for intranasal delivery of interferon-β yielding improved pharmacokinetic and pharmacodynamic results wherein the composition is free of a stabilizer that is a protein or a polypeptide. In certain aspects of the invention, the interferon-β is delivered to the intranasal mucosa along with one or more intranasal delivery-enhancing agent(s) to yield substantially increased absorption and/or bioavailability of the interferon-β and/or a substantially decreased time to maximal concentration of interferon-β in a tissue of a subject as compared to controls where the interferon-β is administered to the same intranasal site alone or formulated according to previously disclosed reports. The enhancement of intranasal delivery of interferon-β according to the methods and compositions of the present invention allows for the effective pharmaceutical use of these agents to treat a variety of diseases and conditions in mammalian subjects.

2007003, Feb 8, 2007

Sep 29, 2006

11/537468

Steven Quay - Seattle WA, US
Alexis Leonard - Maple Valley WA, US
Henry Costantino - Woodinville WA, US
Anthony Sileno - Brookhaven Hamlet NY, US
Joshua Sestak - Kirkland WA, US

A61K 38/22

514009000, 514012000

Methods and compositions containing oxytocin or an oxytocin analog, specifically carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of the invention are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.

2006005, Mar 9, 2006

Oct 6, 2005

11/246406

Steven Quay - Seattle WA, US
Gordon Brandt - Issaquah WA, US
Henry Costantino - Woodinville WA, US

A61K 38/29, A61K 31/195

514012000, 514566000

What is described is a method for treating osteoporosis in a mammal comprising administering intranasally a therapeutically effective amount of a PTH formulation to the mammal wherein the PTH formulation is an aqueous formulation comprised of a PTH peptide and one or more excipients selected from the group consisting of a water-miscible polar organic solvent, a surface active agent, and a chelating agent for cations.

2007007, Apr 5, 2007

Sep 29, 2006

11/536937

Steven Quay - Seattle WA, US
Shu-Chih Quay - Seattle WA, US
Najib Lamharzi - Bothell WA, US
Kristine Fry - Seattle WA, US

A61K 38/21, A61K 38/28, A61K 38/22, A61F 13/02

424448000, 514012000, 514003000, 514009000, 424085600, 424085500, 424085700

A composition comprising a biologically active agent and a permeation enhancing lipid wherein the permeation enhancing lipid is a platelet activating factor antagonist or a biologically inactive a platelet activating factor, and increases permeability of the biologically active agent across a tissue layer. Also disclosed is a process of increasing the permeability of a biological agent across a layer tissue comprising contacting the tissue layer with a composition comprising the biological agent and a permeation enhancing lipid wherein the permeation enhancing lipid is a platelet activating factor antagonist or a biologically inactive platelet activating factor.

2012014, Jun 14, 2012

Aug 27, 2010

13/392042

Steven C. Quay - Seattle WA, US

Atossa Genetics, Inc. - Seattle WA

A61K 31/713, A61P 35/00

514 44 A

Provided in this application are formulations of double stranded RNA molecules and Krebs Cycle analogs that improving ribonuclease stability, reducing off-target effects of a double stranded siRNA molecule, or of reducing interferon responsiveness of a double stranded siRNA molecule using such dsRNA. Also disclosed are methods of treating a primary tumor or a metastasis by contacting circulating tumor cells, a primary tumor, or a metastasis with a described formulation.

2011023, Sep 29, 2011

Aug 5, 2009

13/057741

Steven C. Quay - Seattle WA, US
James McSwiggen - Boulder CO, US
Narendra K. Vaish - Kirkland WA, US
Kathy L. Fosnaugh - Bellevue WA, US
Shaguna Seth - Bothell WA, US

MARINA BIOTECH, INC. - Bothell WA

C12N 5/071, C07H 21/02

435366, 536 245, 435375

The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), capable of decreasing or silencing BIRC5 gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a BIRC5 mRNA. Also provided are methods of decreasing expression of a BIRC5 gene in a cell or in a subject to treat a BIRC5-related disease.

2010010, Apr 29, 2010

Sep 1, 2009

12/552082

Steven C. Quay - Seattle WA, US
James McSwiggen - Boulder CO, US
Narendra K. Vaish - Kirkland WA, US
Mohammad Ahmadian - Carlsbad CA, US

MDRNA, Inc. - Bothell WA

C12N 5/071, C07H 21/02, C12N 5/00

435366, 536 231, 435375

The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), and blunt ended double-stranded ribonucleic acid molecules capable of decreasing or silencing expression of a target gene. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target mRNA. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease or condition associated with the target gene.